Keyphrases
Israel
86%
Aspergillus Fumigatus
40%
Invasive Aspergillosis
39%
Red Blood Cell Aggregation
33%
BNT162b2 Vaccine
28%
Candida Albicans (C. albicans)
28%
Candida Auris
27%
Voriconazole
26%
Mucormycosis
26%
Bacterial Infection
24%
COVID-19
24%
Healthcare Workers
23%
Aurès
23%
Bloodstream Infection
23%
Candidemia
23%
Virulence
22%
Extended-spectrum-lactamase
22%
Pseudomonas Aeruginosa (P. aeruginosa)
22%
Clinical Outcomes
21%
Invasive Fungal Disease
21%
Invasive Candidiasis
21%
Enterobacteriaceae
21%
Multidrug-resistant
20%
Risk Factors
19%
Posaconazole
19%
Confidence Interval
18%
Echinocandins
18%
Bacteremia
18%
Candida
17%
Immunocompromised Patients
17%
Fluconazole
17%
Red Blood Cells
17%
Pseudomonas Aeruginosa Bacteraemia
16%
Third Dose
16%
Israeli
15%
Monotherapy
15%
Angiogenesis
15%
Fluconazole Resistance
15%
Fumigatus
14%
Single Center
14%
Odds Ratio
14%
Antifungal Therapy
14%
Antibiotic Treatment
14%
Randomized Controlled Trial
14%
Invasive Mold Infections
14%
Combination Therapy
14%
Retrospective Cohort Study
13%
BNT162b2
13%
Prospective Cohort Study
13%
Fly Model
13%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
86%
Bloodstream Infection
50%
Cohort Study
38%
Diseases
36%
Invasive Aspergillosis
30%
Pseudomonas aeruginosa
30%
Mould
28%
Antifungal Agent
26%
Candida
24%
Fluconazole
21%
Mucormycosis
20%
Bacterial Infection
20%
Candidemia
17%
Combination Therapy
17%
Enterobacteriaceae
17%
Aspergillus fumigatus
16%
Infectious Agent
16%
Invasive Candidiasis
15%
Monotherapy
15%
Antiinfective Agent
14%
Retrospective Study
14%
Aspergillus
14%
Fibrinogen
14%
COVID-19 Vaccine
13%
Posaconazole
13%
Mycosis
13%
Voriconazole
12%
Bacteriophage
12%
Adverse Event
12%
Antifungal Therapy
11%
Hematologic Malignancy
11%
Candida Auris
11%
Messenger RNA
11%
Clinical Feature
10%
Carbapenem
10%
Mortality Rate
10%
Clinical Trial
10%
Penicillinase
10%
Antibiotic Therapy
9%
Extended Spectrum Beta Lactamase
9%
Randomized Controlled Trial
9%
Chimeric Antigen Receptor
9%
SARS Coronavirus
9%
Acute Heart Infarction
9%
Piperacillin Plus Tazobactam
9%
Antibiotics
9%
Amphotericin B
8%
Echinocandin
8%
Clostridium Difficile Infection
8%
Candida Albicans
8%
Medicine and Dentistry
Infection
100%
Bloodstream Infection
37%
COVID-19
30%
Diseases
24%
Health Care
22%
Pseudomonas aeruginosa
22%
Mucormycosis
21%
Antibiotic Therapy
18%
Penicillinase
17%
Severe Acute Respiratory Syndrome Coronavirus 2
17%
Extended Spectrum Beta Lactamase
17%
Enterobacteriaceae
16%
Mycosis
16%
Odds Ratio
16%
Pathogen
16%
Mortality Rate
15%
Retrospective Study
14%
Blood Culture
14%
Retrospective Cohort Study
13%
Randomized Controlled Trial
13%
Candidemia
13%
Combination Therapy
12%
Hematologic Malignancy
12%
Fungal Infection
12%
Bacteriophage
12%
Invasive Aspergillosis
11%
Fluconazole
11%
Clinical Feature
11%
Carbapenem
10%
Infectious Disease
10%
Human Immunodeficiency Virus
9%
Systemic Candidiasis
9%
Monotherapy
9%
Immunosuppressive Treatment
9%
Arm
9%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
9%
Cohort Analysis
9%
Bacterial Infection
9%
Systemic Mycosis
8%
Brain Abscess
8%
Piperacillin/Tazobactam
8%
Clinical Trial
8%
Clostridium Difficile Infection
8%
Men Who Have Sex with Men
8%
Cat-Scratch Disease
8%
Fecal Microbiota Transplantation
8%
Compassionate Use
8%
Pneumocystis Jirovecii
8%
Malignant Neoplasm
8%
Cross Sectional Study
8%